Synthesis and evaluation of paracetamol esters as novel fatty acid amide hydrolase inhibitors

Journal of Medicinal Chemistry

Volumn 53, Issue 5, 2010, Pages 2286-2298

  Onnis, Valentina ^a   Congiu, Cenzo ^a   Björklund, Emmelie ^b   Hempel, Franziska ^b   Söderström, Emma ^b   Fowler, Christopher J ^b  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (2 (TRIFLUOROMETHYL) PYRIDIN 4 YLAMINO) PHENYL] ACETIC ACID; 2 ARACHIDONOYLGLYCEROL; ACYLGLYCEROL LIPASE; ANANDAMIDE; FATTY ACID AMIDASE; IBUPROFEN; PARACETAMOL; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL MEMBRANE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; HYDROLYSIS; IC 50; LEUKEMIA CELL; NONHUMAN; RAT; RECYCLING; STRUCTURE ACTIVITY RELATION;

AMIDOHYDROLASES; ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONIC ACIDS; BENZOATES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; INHIBITORY CONCENTRATION 50; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; POLYUNSATURATED ALKAMIDES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; SPECTROPHOTOMETRY, INFRARED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77949420579     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901891p     Document Type: Article

References (89)

1. Cravatt, B. F.; Giang, D. K.; Mayfield, S. P.; Boger, D. L.; Lerner, R. A.; Gilula, N. B. Molecular characterization of an enzyme that degrades neuromodulator fatty-acid amides. Nature 1996, 384, 83-87.
2. Giang, D. K.; Cravatt, B. F. Molecular characterization of human and mouse fatty acid amide hydrolases. Proc. Natl Acad. Sci. U.S.A. 1997, 4, 2238-2242.
3. Fowler, C. J.; Jonsson, K.-O.; Tiger, G. Fatty acid amide hydrolase: biochemistry, pharmacology, and therapeutic possibilities for an enzyme hydrolyzing anandamide, 2-arachidonoylglycerol, palmitoylethanolamide, and oleamide. Biochem. Pharmacol. 2001, 52, 517-526.
4. Patricelli, M. P.; Cravatt, B. F. Proteins regulating the biosynthesis and inactivation of neuromodulatory fatty acid amides. Vitam. Horm. 2001, 62, 663-674.
5. Devane, W. A.; Hanus, L.; Breuer, A.; Pertwee, R. G.; Stevenson, L. A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258, 1946-1949.
6. Rodriguez de Fonseca, F.; Navarro, M.; Gomez, R.; Escuredo, L.; Nava, F.; Fu, J.; Murillo-Rodríguez, E.; Giuffrida, A.; Lo Verme, J.; Gaetani, S.; Kathuria, S.; Gall, C.; Piomelli, D. An anorexic lipid mediator regulated by feeding. Nature 2001, 414, 209-212.
7. Fu, J.; Gaetani, S.; Oveisi, F.; LoVerme, J.; Serrano, A.; Rodriguez de Fonseca, F.; Rosengarth, A.; Luecke, H.; Di Giacomo, B.; Tarzia, G.; Piomelli, D. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α. Nature 2003, 425, 90-93.
8. Calignano, A.; La Rana, G.; Giuffrida, A.; Piomelli, D. Control of Pain initiation by endogenous cannabinoids. Nature 1998, 394, 277-281.
9. Lambert, D. M.; Vandevoorde, S.; Jonsson, K.-O.; Fowler, C. J. The palmitoylethanolamide family: a new class of anti-inflammatory agents. Curr. Med. Chem. 2002, 9, 663-674.
10. Cravatt, B. F.; Demarest, K.; Patricelli, M. P.; Bracey, M. H.; Giang, D. K.; Martin, B. R.; Lichtman, A. H. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 9371-9376.
11. Lichtman, A. H.; Shelton, C. C.; Advani, T.; Cravatt, B. F. Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptormediated phenotypic hypoalgesia. Pain 2004, 109, 319-327.
12. Cravatt, B. F.; Saghatelian, A.; Hawkins, E. G.; Clement, A. B.; Bracey, M. H.; Lichtman, A. H. Functional disassociation of the central and peripheral fatty acid amide signaling systems. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 10821-10826.
13. Karsak, M.; Gaffal, E.; Date, R.; Wang-Eckhardt, L.; Rehnelt, J.; Petrosino, S.; Starowicz, K.; Steuder, R.; Schlicker, E.; Cravatt, B. F.; Mechoulam, R.; Buettner, R.; Werner, S.; Di Marzo, V.; Tueting, T.; Zimmer, A. Attenuation of allergic contact dermatitis through the endocannabinoid system. Science 2007, 316, 1494-1497.
14. Cravatt, B. F.; Prospero-Garcia, O.; Suizdak, G.; Gilula, N. B.; Henriksen, S. J.; Boger, D. L.; Lerner, R. A. Chemical characterization of a family of brain lipids that induce sleep. Science 1995, 268, 1506-1509.
15. (a) Huitron-Resendiz, S.; Gombart, L.; Cravatt, B. F.; Henriksen, S. J. Effect of oleamide on sleep and its relationship to blood pressure, body temperature, and locomotor activity in rats. Exp. Neurol 2001, 172, 235-243.
16. (b) Huitron-Resendiz, S.; Sanchez-Alavez, M.; Wills, D. N.; Cravatt, B. F.; Henriksen, S. J. Characterization of the sleep-wake patterns in mice lacking fatty acid amide hydrolase. Sleep 2004, 27, 857-865.
17. Piomelli, D. The endocannabinoid system: from cell biology to therapy. In Cell Biology of Addiction; Madras, B. K., Ed.; Cold Spring Harbor Laboratory Press: Woodbury, NY, 2006; pp 223-237.
18. Bambico, F. R.; Gobbi, G. The cannabinoid CB1 receptor and the endocannabinoid anandamide: possible antidepressant targets. Expert. Opin. Ther. Targets 2008, 12, 1347-1366.
19. Bambico, F. R.; Duranti, A.; Tontini, A.; Tarzia, G.; Gobbi, G. Endocannabinoids in the treatment of mood disorders: evidence from animal models. Curr. Pharm. Des. 2009, 15, 1623-1646.
20. Cravatt, B. J.; Lichtman, A. H. Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. Curr. Opin. Chem. Biol. 2003, 7, 469-475.
21. Lambert, D. M.; Fowler, C. J. The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J. Med. Chem. 2005, 48, 5059-5087.
22. Seierstad, M.; Breitenbucher, J. G. Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors. J. Med. Chem. 2008, 51, 7327-7343.
23. Schlosburg, J. E.; Kinsey, S. G.; Lichtman, A. H. Targeting fatty acid amide hydrolase (FAAH) to treat pain and inflammation. AAPS J. 2009, 11, 39-44.
24. Seierstad, M.; Breitenbucher, J. G. Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors. J. Med. Chem. 2008, 51, 7327-7343.
25. Fezza, F.; De Simone, C.; Amadio, D.; Maccarrone, M. Fatty acid amide hydrolase: a gate-keeper of the endocannabinoid system. Subcell. Biochem. 2008, 49, 101-132.
26. Vandevoorde, S. Overview of the chemical families of fatty acid amide hydrolase and monoacylglycerol lipase inhibitors. Curr. Top. Med. Chem. 2008, 8, 247-267.
27. Boger, D. L.; Miyauchi, H.; Du, W.; Hardouin, C.; Fecik, R. A.; Cheng, H.; Hwang, I.; Hedrick, M. P.; Acevedo, O.; Guimaraes, C. R. W.; Jorgensen, W. L.; Cravatt, B. F. Discovery of a potent, selective, and efficacious class of reversible α-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics. J. Med. Chem. 2005, 48, 1849-1856.
28. Romero, F. A.; Hwang, I.; Boger, D. L. Delineation of a fundamental α-ketoheterocycle substituem effect for use in the design of enzyme inhibitors. J. Am. Chem. Soc. 2006, 128, 14004-14005.
29. Romero, F. A.; Du, W.; Hwang, I.; Rayl, T. J.; Kimball, F. S.; Leung, D.; Hoover, H. S.; Apodaca, R. L.; Breitenbucher, J. G.; Cravatt, B. F.; Boger, D. L. Potentand selective a-ketoheterocycle-based inhibitors of the anandamide and oleamide catabolizing enzyme, fatty acid amide hydrolase. J. Med. Chem. 2007, 50, 1058-1068.
30. Hardouin, C.; Kelso, M. J.; Romero, F. A.; Rayl, T. J.; Leung, D.; Hwang, I.; Cravatt, B. F.; Boger, D. L. Structure-activity relationships of α-ketooxazole inhibitors of fatty acid amide hydrolase. J. Med. Chem. 2007, 50, 3359-3368.
31. Myllymäki, M. J.; Saario, S. M.; Kataja, A. O.; Castillo-Melendez, J. A.; Nevalainen, T.; Juvonen, R. O.; Jaervinen, T.; Koskinen, A. M. P. Design, synthesis, and in vitro evaluation of carbamate derivatives of 2-benzoxazolyl- and 2-benzothiazolyl-(3-hydroxyphenyl)-methanones as novel fatty acid amide hydrolase inhibitors. J. Med. Chem. 2007, 50, 4236-4242.
32. Garfunkle, J.; Ezzili, C.; Rayl, T. J.; Hochstatter, D. G.; Hwang, I.; Boger, D. L. Optimization of the central heterocycle of α-ketoheterocycle inhibitors of fatty acid amide hydrolase. J. Med. Chem. 2008, 51, 4392-4403.
33. DeMartino, J. K.; Garfunkle, J.; Hochstatter, D. G.; Cravatt, B. F.; Boger, D. L. Exploration of a fundamental substituem effect of α-ketoheterocycle enzyme inhibitors: potent and selective inhibitors of fatty acid amide hydrolase. Bioorg. Med. Chem. Lett. 2008, 18, 5842-5846.
34. Maryanoff, B. E.; Costanzo, M. J. Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. Bioorg. Med. Chem. 2008, 16, 1562-1595.
35. Muccioli, G. G.; Fazio, N.; Scriba, E. K. G.; Poppitz, W.; Cannata, F.; Poupaert, H. J.; Wouters, J.; Lambert, M. D. Substituted 2-thioxoimidazolidin-4- ones and imidazolidine-2,4-diones as fatty acid amide hydrolase inhibitors templates. J. Med. Chem. 2006, 49, 411-425.
36. Ahn, K.; Johnson, D. S.; Fitzgerald, L. R.; Liimatta, M.; Arendse, A.; Stevenson, T.; Lund, E. T.; Nugent, R. A.; Nomanbhoy, T. K.; Alexander, J. P.; Cravatt, B. F. Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. Biochemistry 2007, 46, 13019-13030.
37. Kathuria, S.; Gaetani, S.; Fegley, D.; Valino, F.; Duranti, A.; Tontini, A.; Mor, M.; Tarzia, G.; La Rana, G.; Calignano, A.; Giustino, A.; Tattoli, M.; Palmery, M.; Cuomo, V.; Piomelli, D. Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. 2003, 9, 76-81.
38. Sit, S.-Y.; Xie, K. Bisarylimidazolyl fatty acid amide hydrolase inhibitors. Patent WO2002087569, 2002.
39. Hertzog, D. L. Recent advances in the cannabinoids. Expert Opin. Ther. Pat. 2004, 14, 1435-1452.
40. Tarzia, G.; Duranti, A.; Tontini, A.; Piersanti, G.; Mor, M.; Rivara, S.; Plazzi, P. V.; Park, C.; Kathuria, S.; Piomelli, D. Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors. J. Med. Chem. 2003, 46, 2352-2360.
41. Sit, S. Y.; Conway, C.; Bertekap, R.;Xie, K.; Bourin, C.; Burris, K.; Deng, H. Novel inhibitors of fatty acid amide hydrolase. Bioorg. Med. Chem. Lett. 2007, 17, 3287-3291.
42. Mor, M.; Lodola, A.; Rivara, A.; Vacondio, F.; Duranti, A.; Tontini, A.; Sanchini, S.; Piersanti, G.; Clapper, J. R.; King, A. R.; Giorgio Tarzia, G.; Piomelli, D. Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the n-portion of biphenyl-3-yl alkylcarbamates. J. Med. Chem. 2008, 51, 3487-3498.
43. Minkkilä, A.; Myllymäki, M. J.; Saario, S. M.; Castillo-Melendez, J. A.; Koskinen, A. M. P.; Fowler, C. J.; Leppanen, J.; Nevalainen, T. The synthesis and biological evaluation of para-substituted phenolic N-alkyl carbamates as endocannabinoid hydrolyzing enzyme inhibitors. Eur. J. Med. Chem. 2009, 44, 2994-3008.
44. Holt, S.; Nilsson, J.; Omeir, R.; Tiger, G.; Fowler, C. J. Effects of pH on the inhibition of fatty acid amidohydrolase by ibuprofen. Br. J. Pharmacol. 2001, 133, 513-520.
45. Fowler, C. J.; Tiger, G.; Stenström, A. Ibuprofen inhibits rat brain deamidation of anandamide at pharmacologically relevant concentrations. Mode of inhibition and structure-activity relationship. J. Pharmacol. Exp. Ther. 1997, 283, 729-734.
46. Holt, S.; Paylor, B.; Boldrup, L.; Alajakku, K.; Vandevoorde, S.; Sundström, A.; Cocco, M. T.; Onnis, V.; Fowler, C. J. Inhibition of fatty acid amide hydrolase, a key endocannabinoid metabolizing enzyme, by analogues of ibuprofen and indomethacin. Eur. J. Pharmacol. 2007, 565, 26-36.
47. Högestätt, E. D.; Jonsson, B. A.; Ermund, A.; Andersson, D. A.; Bjork, H.; Alexander, J. P.; Cravatt, B. F.; Basbaum, A. I.; Zygmunt, P. M. Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. J. Biol. Chem. 2005, 280, 31405-31412.
48. Lang, W.; Qin, C; Lin, S.; Khanolkar, A. D.; Goutopoulos, A.; Fan, P.; Abouzid, K.; Meng, Z.; Biegel, D.; Makriyannis, A. Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase. J. Med. Chem. 1999, 42, 896-902.
49. Beltramo, M.; Stella, N.; Calignano, A.; Lin, S. Y.; Makriyannis, A.; Piomelli, D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 1997, 277, 1094-1097.
50. Khanolkar, A. D.; Abadji, V.; Lin, S.; Hill, W. A.; Taha, G.; Abouzid, K.; Meng, Z.; Fan, P.; Makriyannis, A. Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. J. Med. Chem. 1996, 39, 4515-4519.
51. Zygmunt, P. M.; Chuang, H.-h.; Movahed, P.; Julius, D.; Högestätt, E. D. The anandamide transport inhibitor AM404 activates vanilloid receptors. Eur. J. Pharmacol. 2000, 396, 39-42.
52. La Rana, G.; Russo, R.; Campolongo, P.; Bortolato, M.; Mangieri, R. A.; Cuomo, V.; Iacono, A.; Raso, G. M.; Meli, R.; Piomelli, D.; Calignano, A. Modulation of neuropathic and inflammatory pain by the endocannabinoid transport inhibitor AM404 [N(4-hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide]. J. Pharmacol. Exp. Ther. 2006, 317, 1365-1371.
53. 1 receptors. Eur. J. Pharmacol. 2006, 531, 280-281.
54. Dani, M.; Guindon, J.; Lambert, C.; Beaulieu, P. The local antinociceptive effects of paracetamol in neuropathic pain are mediated by cannabinoid receptors. Eur. J. Pharmacol. 2007, 573, 214-215.
55. Mallet, C.; Daulhac, L.; Bonnefort, J.; Ledent, C.; Etienne, M.; Chapuy, E.; Libert, F.; Eschalier, A. Endocannabinoid and serotonergic systems are needed for acetaminophen-induced analgesia. Pain 2008, 139, 190-200.
56. Sinning, C.; Watzer, B.; Coste, O.; Nüsing, R. M.; Ott, I.; Ligresti, A.; Di Marzo, V.; Imming, P. New analgesics synthetically derived from the paracetamol metabolite N(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8, 11,14-enamide. J. Med. Chem. 2008, 51, 7800-7805.
57. Sinning, C.; Watzer, B.; De Petrocellis, L.; Di Marzo, V.; Imming, P. Dopamides, vanillylamides, ethanolamides, and arachidonic acid amides of anti-inflammatory and analgesic drug substances as TRPV1 ligands. ChemMedChem 2008, 3, 1956-1964.
58. Maione, S.; De Petrocellis, L.; de Novellis, V.; Moriello, A. S.; Petrosino, S.; Palazzo, E.; Rossi, F. S.; Woodward, D. F.; Di Marzo, V. Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br. J. Pharmacol. 2007, 150, 766-781.
59. Micale, V.; Cristino, L.; Tamburella, A.; Petrosino, S.; Leggio, G. M.; Drago, F.; Di Marzo, V. Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology 2009, 34, 593-606.
60. Congiu, C.; Coceo, M. T.; Lilliu, V.; Onnis, V. New potential anticancer agents based on the anthranilic acid scaffold. Synthesis and evaluation of biological activity. J. Med. Chem. 2005, 48, 8245-8252.
61. Vandevoorde, S.; Jonsson, K.-O.; Fowler, C. J.; Lambert, D. M. Modifications of the ethanolamine head in N- palmitoylethanolamine: synthesis and evaluation of new agents interfering with the metabolism of anandamide. J. Med. Chem. 2003, 46, 1440-1448.
62. Day, T. A.; Rakhshan, F.; Deutsch, D. G.; Barker, E. L. Role of fatty acid amide hydrolase in the transport of the endogenous canabinoid anandamide. Mol. Pharmacol. 2001, 59, 1369-1375.
63. Kaczocha, M.; Hermann, A.; Glaser, S. T.; Bojesen, I. N.; Deutsch, D. G. Anandamide uptake is consistent with rate-limited diffusion and is regulated by the degree of its hydrolysis by fatty acid amide hydrolase. J. Biol. Chem. 2006, 281, 9066-9075.
64. McFarland, M. J.; Porter, A. C.; Rakhshan, F. R.; Rawat, D. S.; Gibbs, R. A.; Barker, E. L. A role for caveolae/lipid rafts in the uptake and recycling of the endogenous cannabinoid anandamide. J. Biol. Chem. 2004, 279, 41991-41997.
65. Thors, L.; Belghiti, M.; Fowler, C. J. Inhibition of fatty acid amide hydrolase by kaempferol and related naturally occurring flavonoids. Br. J. Pharmacol. 2008, 155, 244-252.
66. Long, J. Z.; Li, W.; Booker, L.; Burston, J. J.; Kinsey, S. G.; Schlosburg, J. E.; Pavón, F. J.; Serrano, A. M.; Selley, D. E.; Parsons, L. H.; Lichtman, A. H.; Cravatt, B. F. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat. Chem. Biol 2009, 5, 31-44.
67. Dinh, T. P.; Carpenter, D.; Leslie, F. M.; Freund, T. F.; Katona, I.; Sensi, S. L.; Kathuria, S.; Piomelli, D. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 10819-10824.
68. Blankman, J. L.; Simon, G. M.; Cravatt, B. F. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem. Biol 2007, 14, 1347-1356.
69. Bisogno, T.; Ortar, G.; Petrosino, S.; Morera, E.; Palazzo, E.; Nalli, M.; Maione, S.; Di Marzo, V. Endocannabinoid Research Group. Development of a potent inhibitor of 2-arachidonoylglycerol hydrolysis with antinociceptive activity in vivo. Biochim. Biophys. Acta 2009, 1791, 53-60.
70. Muccioli, G. G.; Labar, G.; Lambert, D. M. CAY10499, a novel monoglyceride lipase inhibitor evidenced by an expeditious MGL assay. ChemBioChem 2008, 9, 2704-2710.
71. Ghafouri, N.; Tiger, G.; Razdan, R. K.; Mahadevan, A.; Pertwee, R. G.; Martin, B. R.; Fowler, C. J. Inhibition of monoacylglycerol lipase and fatty acid amide hydrolase by analogues of 2-arachidonoylglycerol. Br. J. Pharmacol. 2004, 143, 774-784.
72. Saario, S. M.; Salo, O. M.; Nevalainen, T.; Poso, A.; Laitinen, J. T.; Järvinen, T.; Niemi, R. Characterization of the sulfhydryl-sensitive site in the enzyme responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes. Chem. Biol. 2005, 12, 649-656.
73. Hu, J.; Björklund, E.; Fowler, C. J. unpublished preliminary data.
74. Meade, E. A.; Smith, W. L.; DeWitt, D. L. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other nonsteroidal anti-inflammatory drugs. J. Biol. Chem. 1993, 268, 6610-6614.
75. 2 synthases by ibuprofen, naproxen, and indomethacin. Biochem. Pharmacol. 2001, 62, 1587-1595.
76. Gierse, J. K.; Zhang, Y.; Hood, W. F.; Walker, M. C.; Trigg, J. S.; Maziasz, T. J.; Koboldt, C. M.; Muhammad, J. L.; Zweifel, B. S.; Masferrer, J. L.; Isakson, P. C.; Seibert, K. Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity. J. Pharmacol. Exp. Ther. 2005, 312, 1206-1212.
77. Warner, T. D.; Giuliano, F.; Vojnovic, I.; Bukasa, A.; Mitchell, J. A.; Vane, J. R. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc. Natl. Acad. Sci. U.S. A. 1999, 96, 7563-7568.
78. Jones, T. R.; Betteridge, R. F.; Newell, D. R.; Jackman, A. L. Synthesis and biological properties of 3-methyl-10-propargyl-5,8-dideazafolic acid. J. Heterocycl Chem. 1989, 26, 1501-1508.
79. Ezquerra, J.; Pedregal, C.; Lamas, C.; Barluenga, J.; Prez, M.; Garca-Martn, M. A.; Gonzlez, M. J. Efficient Reagents for the Synthesis of 5-, 7-, and 5,7-Substituted Indoles Starting from Aromatic Amines: Scope and Limitations. J. Org. Chem. 1996, 61, 5804-5812.
80. Hino, K; Nakamura, H.; Nagai, Y.; Uno, H.; Nishimura, H. Nonsteroidal antiinflammatory agents. 2. [(Heteroarylamino)-phenyl]alkanoic acids. J. Med. Chem. 1983, 26, 222-226.
81. Skinner, W. A.; Gram, H. F.; Mosher, C. W.; Baker, B. R. J. Am. Chem. Soc. 1959, 81, 4639-4643.
82. Colla, A.; Martins, M. A. P.; Ciar, G.; Krimmer, S.; Fischer, P. Trihaloacetylated enol ethers - general synthetic procedure and heterocyclic ring closure reactions with hydroxylamine. Synthesis 1991, 483-486.
83. Nair, M. G. Colleen O'Neal, P.; Baugh, C. M. Folate analogues altered in the C9-N10 bridge region: N'O-tosylisohomofolic acid and N'O- tosylisohomoaminopterin J. Med. Chem. 1978, 21, 673-677.
84. Boldrup, L.; Wilson, S. J.; Barbier, A. J.; Fowler, C. J. A simple stopped assay for fatty acid amide hydrolase avoiding the use of a chloroform extraction phase. J. Biochem. Biophys. Methods 2004, 60, 171-177.
85. Paylor, B.; Holt, S.; Fowler, C. J. The potency of the fatty acid amide hydrolase inhibitor URB597 is dependent upon the assay pH. Pharmacol. Res. 2006, 54, 481-5.
86. Corrigendum published in Pharmacol. Res., 2007, 55, 80.
87. Rakhshan, F.; Day, T. A.; Blakely, R. D.; Barker, E. L. Carriermediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells, J. Pharmacol. Exp. Ther. 2000, 292, 960-967.
88. Thors, L.; Eriksson, J.; Fowler, C.J. Inhibition of the cellular uptake of anandamide by genistein and its analogue daidzein in cells with different levels of fatty acid amide hydrolase-driven uptake. Br. J. Pharmacol. 2007, 152, 744-750.
89. Karlsson, M.; Pahlsson, C.; Fowler, C. J. Reversible, temperature-dependent, and AM404-inhibitable adsorption of anandamide to cell culture wells as a confounding factor in release experiments. Eur. J. Pharm. Sci. 2004, 22, 181-189.